This story first appeared in The Readout newsletter. Sign up for The Readout and receive STAT’s award-winning biotech news delivered straight to your inbox. Good morning. It’s a very ...

View upcoming earnings forecasts and in-depth analysis of company forecasts.

a Represents net earnings attributable to AbbVie Inc. Acquisition and integration costs primarily reflect integration costs related to the Allergan acquisition, including a one-time gain of $169 ...

LATEST NEWS 05:00 How to pick the life insurance policy that’s right for you 05:00 Dublin AI start-up Glitch set to launch online ad platform 05:00 Movers & Shakers: MSD Ireland, Edelman, Ergo, Fáilte ...

NORTH CHICAGO, Ill. and BOSTON, Oct. 28, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Aliada Therapeutics today announced a definitive agreement under which AbbVie will acquire Aliada, a biotechnology ...

Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

AbbVie aims to best those drugs through its acquisition of Aliada Therapeutics, a biotech whose technology enables large molecules such as antibodies to cross this protective barrier. AbbVie ...

Are you a print subscriber? Activate your account. By Adrianne Pasquarelli - 2 hours 3 min ago By Erika Wheless - 2 hours 3 min ago By Brian Bonilla - 2 hours 3 min ago By Tim Nudd - 2 hours 3 min ...

In the last three months, 11 analysts have published ratings on AbbVie (NYSE:ABBV), offering a diverse range of perspectives from bullish to bearish. The table below provides a snapshot of their ...

The agreement focuses on the discovery, co-development and licensing of new targets that could address neuropsychiatric conditions. Credit: wavebreakmedia ...